Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07403669
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 300 participants
- Registry
-
NCT07403669
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Sweden
- Registry status
- Recruiting
Technical summary
Registry record NCT07403669. Randomized; no masking; primary purpose treatment. Start 2025-10-22 (actual); primary completion 2026-10-22 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
- Acronym
- CHAPERONE-CKM
- Condition
- Acute MI
- Condition
- Heart Failure
- Condition
- Diabetes Mellitus
- Condition
- Kidney Disease
- Intervention (Other)
- CHAPERONE AI
- Intervention (Device)
- CKMiq AI
- Intervention (Other)
- Quality of Life
- Lead sponsor
- Aventyn, Inc.
- Collaborator
- Dignity Health
- Collaborator
- Arizona Heart Foundation
- Collaborator
- Arizona State University
- Collaborator
- University of Arizona
- Collaborator
- University of Phoenix College of Nursing
- Collaborator
- Creighton School of Medicine, Phoenix Arizona
- Collaborator
- Karolinska University Hospital
- Collaborator
- Partnership for Economic Innovation Arizona
- Collaborator
- Kanasu Labs
- Collaborator
- Intel Corporation
Record details
- Record id
cardio:ct-nct07403669- Content hash
b4b61f682d484a44d3e8ddf2c2719276c7548381d64c6fcbf220a86b4acc6d6c